Comienzos
keyboard_arrow_right
keyboard_arrow_right
Mundipharma enter strategic collaboration to co-develop FOLOTYN Allos Therapeutics.
Nutrition

Mundipharma enter strategic collaboration to co-develop FOLOTYN Allos Therapeutics.

Related StoriesDiagnosing traumatic brain injury through a bloodstream test: an interview with Dr KorleyFDA approves LONSURF for treatment of sufferers with metastatic colorectal cancerNew guidance statement on palliative care to be offered at 2015 Palliative Treatment in Oncology Symposium’Mundipharma can be an ideal global partner. Berns, president and chief executive officer of Allos Therapeutics, Inc. ‘We are seeking regulatory approval to market FOLOTYN in Europe for the treatment of individuals with relapsed or refractory peripheral T-cell lymphoma. Our two companies share a vision for getting FOLOTYN to sufferers and believe this collaboration will maximize the development, marketplace and commercialization potential of FOLOTYN in a variety of blood cancers.The group is presenting methods for getting at the elusive understanding of who is dying from HIV/AIDS-related illness in the agricultural countryside of severely affected countries of sub-Saharan Africa, where those infected are tested and formally diagnosed rarely. Weber and his colleagues at USAID and in-country governmental companies have got spent years amending surveys of rural populations in Kenya, Malawi, Mozambique, Zambia and Rwanda to add questions about which, if any, family members have died, their age, their gender, and their place in family members. This is putting a more realistic balance on magnitude of the nagging problem.